ClinicalTrials.gg
RecruitingNCT07335055Updated Mar 5, 2026

A Study for HSK47388 in Participants With Ulcerative Colitis

A Phase 2 interventional study of HSK47388 and Placebo in Ulcerative Colitis (UC), sponsored by Haisco Pharmaceutical Group Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-05.

Sponsored by Haisco Pharmaceutical Group Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 183 studies in Colitis, Ulcerative with a site in China — 72 open to participants now, 95 under way, 25 of them phase 3. Colitis, Ulcerative · China.

Planned enrollment
59th of 135
150 · median 120
Started
2026
with 27 others
Phase 2
34 of 183
14 open now
Primary completion
2027-10
later than 58 of 94 live
Registered
152nd of 183
by date

Among the 183 studies in Colitis, Ulcerative with a site in China, this one is the 59th largest by planned enrollment of the 135 interventional ones that give a count, is one of 28 that started in 2026, is one of 34 in phase 2, reaches primary completion later than 58 of the 94 other live ones, and was the 152nd registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

72 of the 183 studies in Colitis, Ulcerative with a site in China are open now. Recruiting first, the newest first:

66 more — sign in →

All 72 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 183 studies in Colitis, Ulcerative with a site in China, or all of them as a file.
02

Study summary

The purpose of this protocol is to evaluate the efficacy and safety of HSK47388 as therapy in participants with moderately to severely active ulcerative colitis .

03

Conditions studied

  • Ulcerative Colitis (UC)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written must be obtained
  2. Male or female, ≥18 years old and ≤75 years old
  3. Willing and able to comply with study-specific procedures and the requirements of study protocol.
  4. Diagnosis of ulcerative colitis (UC)
  5. Baseline modified Mayo score of 5 to 9 and the endoscopy subscore 2 to 3
  6. Demonstrated an inadequate response, loss of response, or failure to tolerate previous conventional therapy or advanced therapy.

Exclusion criteria

Exclusion Criteria:

  1. Subjects have used treatments within the time frame specified in protocol prior to the baseline visit
  2. Diagnosis of indeterminate colitis, ischemic colitis, Crohn's colitis or clinical findings suggestive of Crohn's disease
  3. Participants with current or prior diagnosis of fulminant colitis and/or toxic megacolon
  4. Presence of a stoma
  5. Presence or history of a fistula
  6. Intra-abdominal or other major surgery performed within 12 weeks before baseline
  7. History of extensive colonic resection
  8. Subjects have laboratory values meeting the criteria in protocol
  9. Concurrent conditions and history of other diseases as described in protocol
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    HSK47388-Dose level 1

    Drug: HSK47388

  • Experimental
    HSK47388-Dose level 2

    Drug: HSK47388

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Participants will be randomized to receive HSK47388, orally starting at Week 0 . At Week-12, all participants will be evaluated for clinical response and responders will enter the maintenance study.

  • DrugPlacebo

    Participants will be randomized to receive Placebo, orally starting at Week 0 . At Week-12, all participants will be evaluated for clinical response and responders will enter the maintenance study.

06

What researchers measure

Primary outcomes

  1. The proportion of patients with clinical response

    Time frame: Week 12

Secondary outcomes

  1. The proportion of patients with clinical remission

    Time frame: Week 12

  2. The proportion of patients with symptomatic remission

    Time frame: Week 12

  3. The proportion of patients with endoscopic remission

    Time frame: Week 12

  4. Proportion of patients with Mayo endoscopic subscore 0

    Time frame: Week 12

  5. Percent change from baseline in Mayo score and modified Mayo score

    Time frame: Week 12

  6. Percent change from baseline in partial Mayo score

    Time frame: Week 12

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Oct 2027, 20 months after the start.

Of 110 industry-sponsored phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 35. This study's planned 20 months is below that.

Counting every sponsor, half of 154 studies reached it within 28 months; a quarter within 22 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2026
First posted
Jan 12, 2026
StartActual
Feb 3, 2026
Primary completionEst.
Oct 15, 2027
CompletionEst.
Feb 2, 2029
Last update
Mar 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07335055
Responsible party
Sponsor
First posted
Jan 12, 2026
Start date
Feb 3, 2026
Primary completion
Oct 15, 2027 (estimated)
Completion
Feb 2, 2029 (estimated)
Last update
Mar 5, 2026

Study contacts

Yongrui Wang
Contact
wangyr@haisco.com
028-67258840

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HSK47388

Start the discussion